JP2025508308A5 - - Google Patents
Info
- Publication number
- JP2025508308A5 JP2025508308A5 JP2024542110A JP2024542110A JP2025508308A5 JP 2025508308 A5 JP2025508308 A5 JP 2025508308A5 JP 2024542110 A JP2024542110 A JP 2024542110A JP 2024542110 A JP2024542110 A JP 2024542110A JP 2025508308 A5 JP2025508308 A5 JP 2025508308A5
- Authority
- JP
- Japan
- Prior art keywords
- csf
- pharmaceutical composition
- expression
- activity
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263309220P | 2022-02-11 | 2022-02-11 | |
| US63/309,220 | 2022-02-11 | ||
| PCT/US2023/062374 WO2023154855A2 (en) | 2022-02-11 | 2023-02-10 | Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508308A JP2025508308A (ja) | 2025-03-26 |
| JP2025508308A5 true JP2025508308A5 (https=) | 2026-02-20 |
Family
ID=87565120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024542110A Pending JP2025508308A (ja) | 2022-02-11 | 2023-02-10 | 神経変性性または神経学的な疾患または障害に対する顆粒球マクロファージコロニー刺激因子ベースの治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250134959A1 (https=) |
| EP (1) | EP4475874A2 (https=) |
| JP (1) | JP2025508308A (https=) |
| KR (1) | KR20240147980A (https=) |
| CN (1) | CN118660715A (https=) |
| AU (1) | AU2023219770A1 (https=) |
| CA (1) | CA3242855A1 (https=) |
| WO (1) | WO2023154855A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023235795A2 (en) * | 2022-06-01 | 2023-12-07 | Partner Therapeutics, Inc. | Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders |
| WO2025168003A1 (zh) * | 2024-02-06 | 2025-08-14 | 上海市第四人民医院 | 一种治疗神经退行性疾病的药物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7785601B2 (en) * | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| JP2023514972A (ja) * | 2020-02-12 | 2023-04-12 | ザ スクリプス リサーチ インスティテュート | 長時間作用型ｇｍ－ｃｓｆおよび使用方法 |
-
2023
- 2023-02-10 AU AU2023219770A patent/AU2023219770A1/en active Pending
- 2023-02-10 JP JP2024542110A patent/JP2025508308A/ja active Pending
- 2023-02-10 EP EP23753693.3A patent/EP4475874A2/en active Pending
- 2023-02-10 US US18/837,235 patent/US20250134959A1/en active Pending
- 2023-02-10 WO PCT/US2023/062374 patent/WO2023154855A2/en not_active Ceased
- 2023-02-10 CA CA3242855A patent/CA3242855A1/en active Pending
- 2023-02-10 KR KR1020247024332A patent/KR20240147980A/ko active Pending
- 2023-02-10 CN CN202380021043.5A patent/CN118660715A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zahir-Jouzdani et al. | Interleukin-6 participation in pathology of ocular diseases | |
| JP2025508308A5 (https=) | ||
| US6537549B2 (en) | Cytokine antagonists for the treatment of localized disorders | |
| Liu et al. | Preferential recruitment of neutrophils into the cerebellum and brainstem contributes to the atypical experimental autoimmune encephalomyelitis phenotype | |
| Amemiya et al. | Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin | |
| US6982089B2 (en) | Cytokine antagonists for neurological and neuropsychiatric disorders | |
| Furlan et al. | Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing–remitting autoimmune encephalomyelitis in Biozzi AB/H mice | |
| US7629311B2 (en) | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers | |
| Hauser et al. | Prophylactic treatment of depression induced by interferon-α | |
| US20010016195A1 (en) | Cytokine antagonists for the treatment of localized disorders | |
| Lerner et al. | Neuropsychiatric toxicity associated with cytokine therapies | |
| US20030185826A1 (en) | Cytokine antagonists for the treatment of localized disorders | |
| US8236306B2 (en) | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers | |
| US9867867B2 (en) | IL-33 and treatment of neurodegenerative diseases | |
| WO2019223581A1 (zh) | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 | |
| JP2021535152A5 (https=) | ||
| US20190008960A1 (en) | IL-12 P40 Monomer, Monoclonal Antibody Against P40 Homodimer and the Combination of the Two for Autoimmune Disease Treatment | |
| Banks et al. | Cytokines and the blood–brain barrier | |
| CN118660715A (zh) | 用于神经退行性或神经系统疾病或病症的基于粒细胞-巨噬细胞集落刺激因子的治疗 | |
| JP2002538207A (ja) | 多発性硬化症治療のための３−シクロプロピルメトキシ−４−ジフルオロメトキシ−ｎ−（３，５−ジクロロピリド−４−イル）ベンズアミド | |
| Chavoshinezhad et al. | Intranasal interferon-beta as a promising alternative for the treatment of Alzheimer's disease | |
| WO2025111752A1 (zh) | 以Lck/Fyn介导STAT3磷酸化为靶点的阻断剂和生物材料的用途 | |
| JP2024518410A5 (https=) | ||
| US20240018231A1 (en) | Intranasal immunotherapt for the treatment of alzheimer's disease | |
| US20240361339A1 (en) | Biomarkers for parkinson's disease |